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Restoration of CD4+ Responses to Copathogens in
HIV-Infected Individuals on Antiretroviral Therapy
Is Dependent on T Cell Memory Phenotype
Catherine Riou,*,†,1 Ramla F. Tanko,*,†,1 Andreia P. Soares,*,† Lindi Masson,*,†,‡
Lise Werner,‡ Nigel J. Garrett,‡ Natasha Samsunder,‡ Quarraisha Abdool Karim,‡
Salim S. Abdool Karim,‡ and Wendy A. Burgers*,†
Antiretroviral therapy (ART) induces rapid suppression of viral replication and a progressive replenishment of CD4+ T cells in
HIV-infected individuals. However, the effect of ART on restoring pre-existing memory CD4+ T cells specific for common
copathogens is still unclear. To better understand the dynamics of Ag-specific CD4+ T cells during ART, we assessed the frequency,
functional capacity, and memory profile of CD4+ T cells specific for Mycobacterium tuberculosis and CMV in 15 HIV-infected
individuals before and 1 y after ART initiation. After ART initiation, the frequency of M. tuberculosis–specific CD4+ T cells
showed little change, whereas CMV-specific CD4+ T cells were significantly lower (p = 0.003). There was no difference in the
polyfunctional or memory profile of Ag-specific CD4+ T cells before and after ART. The replenishment of Ag-specific CD4+ T cells
correlated with the memory differentiation profile of these cells prior to ART. Pathogen-specific CD4+ T cells exhibiting a late
differentiated profile (CD45RO+CD272) had a lower capacity to replenish (p = 0.019; r = 20.5) compared with cells with an early
differentiated profile (CD45RO+CD27+; p = 0.04; r = 0.45). In conclusion, restoration of copathogen-specific memory CD4+ T cells
during treated HIV infection is related to their memory phenotype, in which early differentiated cells (such as most M. tubercu-
losis–specific cells) have a higher replenishment capacity compared with late differentiated cells (such as most CMV-specific cells).
These data identify an important, hitherto unrecognized, factor that may limit restoration of copathogen immunity in HIV-
infected individuals on ART. The Journal of Immunology, 2015, 195: 2273–2281.
T
he hallmarks of untreated HIV infection are a progressive
loss of CD4+ T cells, sustained cellular activation, and
chronic inflammation (1–3). In addition to the numerical
depletion of CD4+ T cells, HIV can also alter the functional ca-
pacity of these cells, impairing their proliferative potential, alter-
ing their cytokine secretion profiles, and changing their phenotypic
characteristics in response to HIVAgs as well as various copathogens
(4–7). Both of these quantitative and qualitative alterations can lead to
increased susceptibility to opportunistic infections, including tuber-
culosis (TB), Candidiasis, and human papilloma virus infection (8).
Indeed, HIV is the best-recognized risk factor for TB disease even
before profound CD4+ T cell deficiency (9, 10). The introduction of
antiretroviral therapy (ART) has drastically decreased morbidity and
mortality in HIV-infected individuals (11), inducing a rapid reduction
of plasma viral load and a progressive repletion of CD4+ T cells (12).
Although the clinical benefit of ART is undeniable, the extent to
which ART can fully normalize functional immunity remains unclear
(13). HIV-infected individuals on ART exhibit a differential degree of
recovery of copathogen-specific CD4+ T cell responses, depending on
the pathogen they target (14–20). For example, it has been shown that
the restoration of CMV-specific CD4+ T cells occurs early after ART
(19), but appears to be short-lived (15). Conversely, Candida-specific
CD4 responses recover slowly (16). Contrasting data exist on the
degree of recovery of Mycobacterium tuberculosis–specific CD4+
T cell responses upon ART. Jambo et al. (20) showed in a cross-
sectional study that the frequency and polyfunctional profile of
M. tuberculosis–specific CD4+ T cell responses were similar in ART-
naive or treated individuals, whereas Sutherland et al. (18) reported
that ART increases the polyfunctional capacity of these cells. Other
studies described only a partial reconstitution of M. tuberculosis–
specific CD4+ T cell responses after ART (14, 17).
It is of particular importance to define the factors that associate
with successful pathogen-specific CD4+ T cell recovery upon ART,
as limited “normalization” of functional CD4+ T cell responses
could account for sustained incidence of opportunistic infections.
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Several parameters influence the degree and dynamics of recovery of
the overall CD4+ T cell compartment in response to ART, such as
age, CD4 count at the time of treatment initiation, and timing of
ART initiation after HIV infection (21–23). However, it is still un-
clear why CD4+ T cells of different pathogen specificities have
different profiles of restoration, and the mechanisms mediating this
variable recovery of memory CD4+ T cells to copathogens are still
incompletely understood. Thus, to better understand the effect of
successful ART on the dynamics of recovery of copathogen-specific
CD4+ T cells, we compared the magnitude, functional capacity, and
memory differentiation profiles of M. tuberculosis– and CMV-
specific CD4+ T cells before and 1 y after ART initiation in a co-
hort of HIV-infected individuals and HIV-uninfected controls.
Materials and Methods
Study participants
Blood samples were collected from 15 women participating in the CAP-
RISA 002 study, a cohort study following HIV-infected women from HIV
seroconversion until 5 y on treatment. The cohort is situated in KwaZulu-
Natal, South Africa, and has been previously described (24, 25). Partic-
ipants were selected based on sample availability. Blood samples from
nine HIV-uninfected participants were provided from the CAPRISA 004
vaginal microbicide (1% tenofovir) gel trial (26). An additional 14 HIV-
uninfected participants from CAPRISA 004 were studied for immune
activation. HIV-uninfected participants were from the same community as
the HIV-infected individuals and age-matched; they were either in the
preintervention phase or the placebo arm of the trial. For HIV-infected
individuals, the time of infection was estimated either as the same date
as a prospective RNA-positive/Ab-negative measurement or taken as the
midpoint between the last Ab negative test and first Ab-positive ELISA
test. Participants in the cohort were offered ART according to South African
national HIV treatment guidelines (at a CD4 count of ,200 cells/mm3
prior to October 2012; ,350 cells/mm3 until the present). Eight of the 15
participants were taking standard first-line therapy (TDF/3TC/EFV), 3
were on ddI-EC/3TC/EFV, and 1 each on d4T/3TC/EFV, TDF/3TC/NVP,
d4T/3TC/NVP, and AZT/3TC/LPV/r. Two participants switched drug
regimens while on study, namely CAP200 (EFV/3TC/ddI-EC to EFV/3TC/
TDF at month 11) and CAP255 (EFV/3TC/d4T to EFV/3TC/AZTat month
10). No participants had active TB during the study period or exhibited any
immune reconstitution disease upon HIV treatment. Ethical approval for
the study was obtained from the University of KwaZulu-Natal and Uni-
versity of Cape Town Research Ethics Committees. All participants pro-
vided written informed consent to participate in the study.
Determination of plasma viral load and CD4 counts
Plasma HIV viral loads and CD4 counts were quantified at each study visit.
Over the course of the study, the viral load PCR assay switched from Roche
AMPLICORHIV-1 monitor test version 1.5 (lower detection limit [LDL] of
400 RNA copies/ml), to Roche TaqMan version 1.0 on June 1, 2010 (LDL
40 RNA copies/ml), and then to Roche TaqMan version 2.0 on January 9,
2012 (LDL 20 RNA copies/ml). Absolute blood CD4 and CD8 T cell counts
were measured using the FACSCalibur TruCOUNT method (BD Bio-
sciences) and expressed as cells/mm3. Plasma samples matching the visits
where PBMC were studied were tested for Abs to CMV and CMV DNA.
Seropositivity was determined using the Cobas CMV IgG Assay (Roche),
and CMV viral load was detected and quantified using a CMV R-gene
PCR kit (Argene), with a detection limit of 30 copies/ml.
Cell preparation
PBMC were isolated by standard Ficoll–Hypaque density gradient cen-
trifugation (Amersham Pharmacia) and cryopreserved in 90% heat-
inactivated FCS (Invitrogen) plus 10% DMSO and stored in liquid nitro-
gen until needed. Cryopreserved PBMC were thawed and rested in R10
(RPMI 1640 containing 10% heat-inactivated FCS [Sigma-Aldrich] and
50 U/ml of penicillin-streptomycin) at 37˚C and 5% CO2 for 8 h prior to
Ag stimulation.
Ags and cell stimulation
Following resting, PBMC were stimulated using M. tuberculosis Purified
Protein Derivative (10 mg/ml; Statens Serum Institute), a pool of CMV
peptides consisting of 138 peptides (15-mers overlapping by 11 aa) cov-
ering the entire HCMV pp65 protein (2 mg/ml; National Institutes of
Health AIDS Reagent Program) and staphylococcal enterotoxin B (SEB;
2.5 mg/ml; Sigma-Aldrich), used as a positive control. Of note, we found
no major differences in the memory profile, cytokine secretion potential,
and polyfunctional capacity between peptide and protein-stimulated PBMC
(R. Bunjun, C. Riou, A.P. Soares, N. Thawer, T.L. Muller, A. Kiravu,
Z. Ginbot, W. Hanekom, G. Walzl, R.J. Wilkinson, and W.A. Burgers, man-
uscript in preparation). Stimulations were performed in the presence of co-
stimulatory Abs anti-CD28 and anti-CD49d (both at 1 mg/ml; BD Biosciences)
at 37˚C for 16 h. Brefeldin A (Sigma-Aldrich) was added after 1 h at a con-
centration of 10 mg/ml. Surface and intracellular cytokine staining was per-
formed at the end of the incubation period. Sufficient cells were available for
assessing CMV and SEB responses in only 12 out of 15 HIV-infected partic-
ipants.
Surface phenotypic and intracellular cytokine staining and
flow cytometry
The following Abs were used for surface and intracellular staining: CD3–
allophycocyanin-H7 (SK7; BD Biosciences), CD4–PE-Cy5.5 (S3.5; Invi-
trogen), CD8-Qdot 705 (3B5; Invitrogen), CD27–PE-Cy5 (1A4CD27;
R&D Systems), CD45RO-ECD (UCHL1; R&D Systems), IFN-g–Alexa
Fluor 700 (B27; BD Biosciences), IL-2–APC (MQ1-17H12; BD Bio-
sciences), TNF-a–PE-Cy7 (MAb11; eBioscience), CD14–Pacific Blue
(T€uk4; Invitrogen), CD19–Pacific Blue (SJ25-CI; Invitrogen), and a violet
amine viability dye (“Vivid”; Molecular Probes). All Abs were titrated to
obtain optimal concentrations prior to use. After stimulation, PBMC were
first stained with Vivid for 20 min at room temperature. Cells were then
surface stained with CD4, CD8, CD45RO, CD27, CD14, and CD19 Abs.
Cells were fixed and permeabilized using Cytofix/Cytoperm buffer (BD
Biosciences) and stained intracellularly with CD3, IL-2, TNF-a, and IFN-g.
Cells were then resuspended in 13 CellFix (BD Biosciences). Samples
were acquired on a BD Fortessa using FACSDiva software and analyzed
using FlowJo (version 9.8.2; Tree Star). The gating strategy is presented in
Supplemental Fig. 1. A positive cytokine response was defined as at least
twice the background (in the presence of costimulatory Abs and no Ag).
For phenotyping the memory profile of cells producing cytokines, a cutoff
of 40 events was used. Polyfunctionality of Ag-specific cells was analyzed
using Pestle (version 1.7) and Spice (version 5.35) software (27). Immune
activation was measured by surface staining of unstimulated cells using the
CD3, CD4, CD8, CD14, and CD19 Abs listed above, as well as CD38-
APC (HIT2) and HLA-DR–allophycocyanin-Cy7 (L243) (both BD Bio-
sciences), along with the inclusion of Vivid.
Statistical analysis
Statistical analyses were performed using GraphPad Prism (version 5.0; San
Diego, CA). Nonparametric statistical tests were used for all comparisons.
The Mann–Whitney U test and Wilcoxon signed-rank test were used for
unmatched and paired samples, respectively, and the Kruskal–Wallis ANOVA
using Dunn’s test for multiple comparisons. Correlations were performed
using the Spearman rank test. A p value ,0.05 was considered statistically
significant.
Results
Effect of ART on the restoration of copathogen-specific CD4+
T cells
In order to better understand the replenishment dynamics of CD4+
T cells specific for copathogens in HIV-infected individuals on
treatment, we studied 15 HIV-infected individuals before and after
ART initiation. The cohort consisted of women infected with HIV-
1 for a median of 4.9 y (interquartile range [IQR]: 3.8–5.8 y) at the
time of treatment initiation (Table I). Pre-ART samples were ob-
tained at a median of 1.7 mo (IQR: 0.8–2.5) prior to starting ART.
The median plasma viral load was 21,955 HIV RNA copies/ml
(IQR: 4,743–52,800), and the median CD4 count was 289 cells/mm3
(IQR: 193–322). After a median of 12 mo of treatment (IQR: 11–
12.3 mo), all individuals exhibited some degree of viral suppres-
sion (p , 0.0001, Supplemental Fig. 2A), which was below the
limit of detection of the assay in 12 out of 15 individuals and
,400 RNA copies/ml in the remainder. An increase in absolute
CD4 count occurred in 13 out of 15 individuals over the period
measured (p , 0.0001; Supplemental Fig. 2B). The median fold
change in absolute CD4 count was 1.9 (IQR: 1.6–2.3), and when
2274 RESTORATION OF COPATHOGEN-SPECIFIC CD4 CELLS AFTER ART












adjusted for length of treatment, the replenishment rate of CD4+
T cells was 20 cells/mm3/month (IQR: 14–26, data not shown);
this was accompanied by a concomitant doubling of the CD4/CD8
ratio (0.27 versus 0.66; p = 0.0007; Supplemental Fig. 2C). As
previously reported (21–23), the degree of CD4 reconstitution
was inversely related to absolute CD4 count at ART initiation
(p , 0.0001; r = 20.85) and the duration of HIV infection
(p = 0.016; r = 20.61, data not shown). We also measured im-
mune activation before and after ART using the markers CD38
and HLA-DR. There was a significant reduction in CD4+ and
CD8+ T cells coexpressing CD38+ and HLA-DR+ (p = 0.0002 and
p = 0.0001; Supplemental Fig. 2D), as well as HLA-DR+ alone
(p = 0.0001 for both subsets). Residual levels of immune activation
after 1 y of ART remained significantly greater than healthy, HIV-
uninfected individuals for both markers (Supplemental Fig. 2D). We
found no association between the degree of CD4 reconstitution and
CD4+ T cell activation before or after ART (data not shown).
To determine whether the dynamics of copathogen-specific
CD4+ T cells mirror the reconstitution of the total CD4+ T cell
population, we measured the magnitude of M. tuberculosis– and
CMV-specific CD4+ T cell responses, as well as SEB-reactive
CD4+ cells, before and after ART initiation. Fig. 1A shows rep-
resentative flow cytometry plots of cytokine production (IFN-g,
IL-2, and TNF-a) by CD4+ T cells in response to M. tuberculosis,
CMV, and SEB stimulation in one HIV-infected patient (CAP267).
At baseline (before ART initiation), 11 out of 15 individuals tested
had a detectable M. tuberculosis response, with a median fre-
quency of 0.08% of total CD4+ T cells (range, 0–0.9%; Fig. 1B).
CMV responses were detected in 10 out of 12 individuals tested,
and the median frequency was 0.35% (range: 0–4.1%). SEB
responses were detectable in 12 out of 12 participants with a
median frequency of 16% (range: 8.6–32.5%). The frequency
of M. tuberculosis–specific and SEB-responding CD4+ T cells
were comparable pre- and post-ART, whereas the frequency of
CMV-specific CD4+ T cells was significantly lower after treatment
(median 0.35 versus 0.14%, p = 0.003; Fig. 1B). To take into
account variation in absolute CD4 counts across the cohort, the
absolute number of Ag-specific CD4+ T cells was calculated. The
number of M. tuberculosis–specific and SEB-responding CD4+
T cells increased significantly after ART (p = 0.033 and p = 0.016,
respectively), whereas the number of CMV-specific CD4+ T cells
remained unchanged upon treatment (Fig. 1C), consistent with the
decreased frequency in the context of increases in absolute CD4
numbers. Overall, these data reveal that the dynamics of recon-
stitution of Ag-specific CD4+ T cells vary according to their
pathogen specificity.
Relationship between the dynamics of restoration of total and
copathogen-specific CD4+ T cells
To further investigate the restoration dynamics of copathogen-
specific CD4+ T cells, we examined the relationship between
the fold change in the absolute number of Ag-specific CD4+
T cells pre- and post-ART (in individuals with detectable Ag re-
sponses at both time points, n = 11 for M. tuberculosis, n = 10 for
CMV, and n = 12 for SEB), and the absolute total CD4 count
variation. Fig. 2A shows that although the magnitude of cell re-
plenishment of M. tuberculosis–specific and SEB-responding
CD4+ T cells was comparable to that of total CD4+ T cells (an
∼2-fold increase over the 12 mo of ART), the extent of restoration
of CMV-specific CD4+ T cells was significantly lower (p = 0.018,
p = 0.013, and p = 0.0008, to M. tuberculosis, SEB, and total
CD4+ cells, respectively). Consistent with these observations, the
degree of restoration of M. tuberculosis– and SEB-responding
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ery, as measured in fold-change of the absolute CD4 count, with
a slope close to 1 (Fig. 2B). In contrast, for CMV-specific CD4+
T cell responses the slope was 0.37, indicating a reduced replen-
ishment rate of these cells compared with the total CD4 com-
partment (Fig. 2B). Of note, although all study participants were
CMV seropositive, none had detectable CMV viral replication at
either visit, pre- or post-ART, indicating that a difference in CMV
Ag load at the two visits was not a contributing factor to the re-
duced replenishment capacity of CMV-specific T cells.
Effect of ART on the functional capacity of copathogen-specific
CD4+ T cells
ART has been shown to gradually restore the polyfunctional capacity
of HIV-specific T cells (28, 29), but the effect of ART on the
functionality of CD4+ T cells specific for other pathogens is un-
clear. Thus, we evaluated the cytokine secretion profiles of
M. tuberculosis–, CMV-, and SEB-reactive CD4+ T cells before
and after ART initiation in detail (Fig. 3). We included nine HIV-
uninfected individuals in this analysis for comparison. Our first
finding was that the cytokine production profile of CD4+ T cells
varied significantly according to their specificity (p = 0.002;
Fig. 3A), with M. tuberculosis–specific responses consisting of
a greater proportion of polyfunctional cells producing all three
cytokines, in addition to a predominant TNF-a monofunctional
subset (∼40% of the response), whereas CMV-specific CD4+ re-
sponses exhibited predominantly a IFN-g+TNF-a+ phenotype
(∼60%; Fig. 3B). ART did not significantly alter the cytokine
secretion profile of CD4+ T cells from baseline, regardless of their
specificity for M. tuberculosis, CMV, or SEB (Fig. 3A, 3B).
Moreover, the polyfunctional characteristics of M. tuberculosis–
specific and SEB-responsive CD4+ T cell responses were com-
parable to those observed in HIV-uninfected individuals. In con-
trast, CMV responses were significantly skewed in HIV-infected
individuals compared with HIV-uninfected subjects (p = 0.016
and p = 0.045 for pre- and post-ART; Fig. 3A), with a lower
proportion of cells coproducing IFN-g, IL-2, and TNF-a, and
a higher proportion of IFN-g monofunctional cells (Fig. 3B).
These data demonstrate that, unlike for M. tuberculosis–specific
CD4 responses, HIV infection impaired the functional potential of
CMV-specific CD4 responses toward a less polyfunctional profile,
and 1 y of ART did not restore the CMV functional profile.
Impact of the memory phenotype of pathogen-specific CD4+
T cells on their replenishment potential upon ART
Depending on their memory differentiation profile, CD4+ T cells
are endowed with distinct survival and proliferation capacities (30,
31). Thus, to investigate whether the cell maturation phenotype
could impact the replenishment capacity of copathogen-specific
CD4+ T cells, we first compared the differentiation profiles of
M. tuberculosis– and CMV-specific CD4+ T cells at baseline, prior
to ART initiation. Fig. 4A shows a representative contour plot of
distinct memory subsets in the CD4 compartment pre-ART in one
HIV-infected individual. Based on the expression of CD45RO and
CD27, we were able to discriminate four different memory sub-
populations (32), namely: naive (CD45RO2CD27+), early differen-
tiated (ED; CD45RO+CD27+, encompassing central and transitional
FIGURE 1. Effect of ART on M. tuberculosis (Mtb)-, CMV-, and SEB-specific CD4+ T cell responses. (A) Representative flow cytometry plots of the
expression of TNF-a, IFN-g, and IL-2 from CD4+ T cells after stimulation withM. tuberculosis (Mtb) and CMVAgs and SEB, in one study participant. NS
corresponds to unstimulated PBMC. The frequency of cytokine-producing cells expressed as a percentage of the total CD4+ T cell population are indicated.
Frequency (B) and absolute number (C) of M. tuberculosis–, CMV-, and SEB-specific CD4+ T cell responses before and after ART. Horizontal bars
represent the median. Statistical comparisons were performed using a Wilcoxon matched-pairs test.
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memory subsets), late differentiated (LD; CD45RO+CD272, en-
compassing effector memory cells), and terminally differentiated
(CD45RO2CD272, or effector cells). In HIV-infected subjects,
although M. tuberculosis– and CMV-specific CD4+ T cells were
represented in both ED and LD subsets, they comprised significantly
distinct profiles (Fig. 4B, left panel). M. tuberculosis–specific cells
exhibited primarily an ED profile (median 51%, interquartile range
[IQR] 42–62), whereas CMV-specific cells demonstrated a substantial
enrichment of the LD phenotype (median 73%, IQR 48–86), as
previously described (33). Of note, ART did not markedly alter the
overall memory differentiation profile of M. tuberculosis–specific or
CMV-specific CD4+ T cells (Supplemental Fig. 3). In addition, HIV-
uninfected individuals exhibited similarly distinctive memory CD4
differentiation profiles for M. tuberculosis and CMV (Fig. 4B, right
panel).
We next investigated the relationship between the memory
phenotype of pathogen-specific CD4+ T cells at the time of ART
initiation and the capacity of these cells to be maintained and/or
replenished upon treatment. Fig. 5A shows that the fold change
in the absolute number of pathogen-specific CD4+ T cells over
12 mo on ART inversely correlated with the proportion of cells
exhibiting a late differentiated phenotype (p = 0.019; r = 20.5).
Consistent with this, a positive correlation was observed between
the fold change in the absolute number of pathogen-specific CD4+
T cells and the proportion of these cells exhibiting an ED phe-
notype (p = 0.04; r = 0.45). Of note, the proportion of LD
FIGURE 2. Restoration dynamics of M. tuberculo-
sis– (Mtb), CMV-, and SEB-specific CD4+ T cells after
ART. (A) Fold change in the total, M. tuberculosis–,
CMV-, and SEB-specific absolute CD4+ T cell count
over 12 mo of ART. The horizontal dotted line indi-
cates no change from the baseline pre-ART time point.
Statistical comparisons were performed using a non-
parametric Mann–Whitney U test. (B) Association
between the fold change of the absolute number of Ag-
specific CD4+ T cells and the fold change in the ab-
solute CD4 count pre- and post-ART. Statistical asso-
ciations were performed by a two-tailed nonparametric
Spearman rank correlation. The solid line represents
a linear regression fit, and the dashed line depicts the
ideal slope of 1.
FIGURE 3. Polyfunctional capacity of
M. tuberculosis– (Mtb), CMV-, and SEB-specific
CD4+ T cells in HIV-infected and uninfected
individuals pre- and post-ART. Pie charts (A) and
graphs (B) representing the cytokine secretion
ability of M. tuberculosis–, CMV-, and SEB-
specific CD4+ T cell responses in HIV-uninfected
individuals (n = 9) and HIV-infected individuals
pre- and post-ART initiation. Each section of the
pie chart represents a specific combination of
cytokines, as indicated by the color at the bottom
of the graph. Horizontal bars depict the median
with interquartile range indicated. Statistical
comparisons were performed using a Wilcoxon
rank-sum test. *p , 0.05, **p , 0.01.
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M. tuberculosis–specific CD4+ T cell responses (in the absence of
CMV responses) also correlated inversely with the fold change in
the absolute number of M. tuberculosis–specific cells (r = 20.62;
p = 0.038; data not shown), and so too when naive-like M. tu-
berculosis–specific cells were grouped together with ED cells, we
observed a trend toward a positive association with the fold
change in the absolute number of M. tuberculosis–specific cells
(r = 0.54; p = 0.05; data not shown). This relationship between the
memory profile and the ART-induced repletion potential of
pathogen-specific CD4+ T cells is further illustrated in Fig. 5B,
showing specific examples from two participants. In CAP257, in
which the pre-ART CMV-specific CD4 response showed an en-
richment in cells with an LD phenotype (82%), their ability to
expand over 12 mo on ART was considerably lower than M. tu-
berculosis–specific CD4 responses, characterized by an ED phe-
notype (77.4%) (fold change 1.2 for the CMV response versus 2.8
for the M. tuberculosis response). In CAP244, in which the
memory profile of both M. tuberculosis and CMV-specific re-
sponses were similar (∼60% of LD cells), the fold change in the
absolute number of CD4+ T cells to both pathogens was compa-
rable.
Overall, these data reveal that the ability of copathogen-specific
memory CD4+ T cells to expand upon ART appears to be related
to their memory phenotype, in which ED cells have a higher re-
plenishment capacity compared with LD cells.
Discussion
The introduction of ART has changed the clinical pattern of HIV
infection significantly, with considerable reductions in morbidity
and mortality. Although it is clearly established that ART leads to
a progressive replenishment of the CD4+ T cell compartment in the
majority of cases, the extent to which pre-existing copathogen-
specific CD4+ T cells are restored, and the causes of variable
restoration, are poorly defined. In this study, we investigated the
FIGURE 4. Memory profiles of M. tuberculosis–
(Mtb) and CMV-specific CD4+ T cells in HIV-infected
and uninfected individuals. (A) Representative example
of total CD4 memory subset distribution in one HIV-
infected individual. Naive (CD45RO2CD27+), ED
(CD45RO+CD27+), LD (CD45RO+CD272), and TD
(CD45RO2CD272). The frequencies of each subset are
indicated. (B) Memory profile of M. tuberculosis– and
CMV-specific CD4+ T cells in HIV-infected individuals
pre-ART (left panel) and HIV-uninfected individuals
(right panel). Results are shown as box and whisker
(10–90 percentile) plots. Each dot depicts an individual,
and the horizontal bar is the median. Statistical com-
parisons were performed using a one-way ANOVA
nonparametric Kruskal–Wallis test.
FIGURE 5. Relationship between the
memory profile of M. tuberculosis– (Mtb)
and CMV-specific CD4+ T cells and the
dynamics of restoration of these cells. (A)
Association between the proportion of Ag-
specific CD4+ T cells exhibiting an LD (top
panel) or ED (bottom panel) profile with the
fold change in Ag-specific CD4+ T cell
absolute count after ART. Statistical asso-
ciations were performed by a two-tailed
nonparametric Spearman rank correlation.
(B) Representative examples of the memory
profile of M. tuberculosis– or CMV-specific
CD4+ T cells pre-ART in two individuals.
The frequencies of each subset are indi-
cated. For each example, the fold change in
Ag-specific absolute CD4+ T cell count pre-
and post-ART is indicated at the top of each
plot.
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dynamics of restoration of memory CD4+ T cells specific for
a bacterial copathogen (M. tuberculosis) and a viral pathogen
(CMV) in 15 HIV-infected individuals in response to ART. Our
main finding was that the extent of reconstitution of pathogen-
specific cells was related to their memory differentiation profile
at the time of ART initiation, in which cells exhibiting an ED
memory profile (including central memory and transitional memory
cells) had a higher replenishment potential compared with LD
(effector memory) T cells.
Multiple mechanisms contribute to the increase in CD4+ T cells
in blood in response to antiretroviral treatment for HIV (34). Over
the first few months of ART, there is a redistribution of CD4+
T cells from the lymph nodes to the blood (35, 36), leading to
a rapid initial rise in CD4+ counts. Moreover, homeostatic cell
proliferation (37), decreased cell death (38) and increased thymic
output (39, 40) also play a role in the replenishment of CD4+
T cells. Although the CD4 absolute cell count at the time of
treatment initiation is one of the main factors dictating the level to
which CD4+ T cells are restored (21, 23), other parameters such as
the activation level of T cells at the time of treatment (41), age
(42, 43), or active coinfections (44, 45) also influence the degree
of reconstitution of the CD4 compartment. Thus, CD4+ T cell
recovery upon ART appears to be dependent on both the extent
of immune damage at the time of treatment initiation and the
regenerative capacities of these cells.
We demonstrate in this study that despite successful viral sup-
pression and robust CD4 gains in the majority of participants, the
dynamics of M. tuberculosis– and CMV-specific CD4+ T cell re-
covery were distinct. This shows that not all T cell subpopulations
have the same potential to be replenished. Several factors and/or
cellular attributes could account for these differences. First, the
regenerative capacities of pathogen-specific CD4+ T cells could be
determined by their intrinsic ability to survive or proliferate, and it
has been clearly established that CD4+ T cells exhibiting an ED
memory profile have an enhanced survival and proliferative po-
tential compared with cells with an LD phenotype (30, 31). Our
data are in accordance with these observations, showing that the
extent of replenishment of pathogen-specific CD4+ T cells cor-
relates with their memory status, with superior recovery observed
for Ag-specific CD4+ T cells exhibiting an early memory phe-
notype. Mechanistically, cell responsiveness to common g-chain
cytokines may account for the distinct renewal potential of these
different cell subsets (46–48). In our study, the replenishment
potential of M. tuberculosis– or CMV-specific CD4+ T cells did
not associate with their ability to produce IL-2 (data not shown);
however, we have observed that responsiveness to IL-7 dis-
tinguishes ED and LD CD4+ subsets, with ED memory T cells
being more responsive to exogenous IL-7 and IL-2 (as measured
by Stat5 phosphorylation), compared with LD memory CD4+ T cells
(C. Riou, unpublished observations). Further analysis comparing the
level of expression of cytokine receptors and cytokine-induced pro-
liferation potential betweenM. tuberculosis– and CMV-specific CD4+
T cells would be needed to define the role of these signaling pathways
in the restoration of immune memory cells upon ART.
Although M. tuberculosis responses displayed primarily an ED
phenotype, there were substantial interindividual differences,
ranging from 30–75% of the response. The CD4+ memory profile
is dictated by numerous factors, including continual Ag exposure
in high burden settings (49), previous TB, TB treatment, and cure
(50–52). A recent study carried out in a similar geographic setting
as the current study noted dynamic changes in the T cell response
to M. tuberculosis in the context of latent TB infection and HIV
coinfection (53). It is worth noting that we also detected Ag-
specific cells with a naive-like phenotype, previously described
for M. tuberculosis and other infections (51, 54, 55). Although
making up only a minor proportion of the total M. tuberculosis– and
CMV-specific response, these cells expanded post-ART in the ma-
jority of individuals compared with other memory subsets, that were
characterized by more variable expansion and contraction. For CMV,
this expansion led to a significantly greater frequency of this subset
after ART. These cells may fall within the recently described memory
stem cell subset, comprising memory cells endowed with a greater
ability to proliferate and persist long-term compared with central
memory (56, 57). Thus, the composition of the memory pool at the
time of ART initiation may influence the restoration of Ag-specific
CD4+ T cells.
To determine whether short-term ART affected not just quan-
titative but also qualitative aspects of copathogen immunity, we
assessed the ability of cells to simultaneously secrete multiple
cytokines, which for some infections, such as HIV and leish-
maniasis, are a correlate of immune control or protection (58, 59).
Although the significance of polyfunctional cells in TB is unclear
(48), we demonstrated that .50% of M. tuberculosis–specific
CD4+ cells produced three or two cytokines simultaneously, a profile
that did not significantly change after ART; moreover, this was
similar to the profile from HIV-uninfected individuals. Our data are in
apparent contrast to previous findings (18) showing that ART leads to
an improved polyfunctional profile in M. tuberculosis–specific CD4+
T cell after short-term treatment, but this may be due to cohort dif-
ferences, as the participants in that study were characterized by more
advanced immunosuppression and higher viral loads than in the
current study. Because it has been reported that the impairment of the
functional capacity of M. tuberculosis–specific CD4+ T cells is re-
lated to HIV disease status (60), it is likely that differences in the
severity of HIV pathology at the time of treatment initiation between
the two studied groups could account for these discrepancies. The
polyfunctional profile we observed for CMV-specific CD4+ cells is
consistent with that previously reported (33), with simultaneous IFN-g
and TNF-a, and IFN-g alone dominating the response. The CMV
profile also did not change after ART and in this case was less pol-
yfunctional compared with HIV-infected individuals. Our study only
examined paired samples from 12 mo after ART, and it is possible
that prolonged ART may restore CMV functional profiles (29).
It is important to note that although we demonstrate an expansion
of M. tuberculosis–specific CD4+ T cells after ART, restoration of
the magnitude and measures of functionality of the M. tubercu-
losis–specific CD4+ Th1 response determined by the production of
three cytokines is a coarse measure of functional immunity to TB
and may not reflect protective immunity. Several additional CD4+
T cell subsets and cytokines contribute to TB immunity (61–64),
and we have found an even greater diversity of CD4+ T cell
subsets specific for M. tuberculosis (C. Riou, N. Strickland,
A.P. Soares, B. Corleis, D.S. Kwon, E.J. Wherry, R.J. Wilkinson,
and W.A. Burgers, submitted for publication). An additional issue is
that we do not know the extent of pathogen-specific CD4+ recovery
in tissues upon ART, which appears defective for TB in the lungs
even after prolonged viral suppression (20). These considerations
may account for the persistently greater susceptibility of success-
fully treated HIV-infected individuals to TB (65).
Our study had several limitations. We were constrained by the
availability of paired samples prior to and after ART, limiting us to
studying 15 individuals in detail. Testing the generalizability of our
findings in larger cohorts is warranted. Also, we focused our study
on short-term restoration of pathogen-specific immunity (after 1 y
of ART), and although study participants exhibited suppressed HIV
replication, decreased immune activation, and improved CD4
counts, studying responses after longer-term therapy may provide
further important insights and more definitive conclusions on the
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restoration of pathogen-specific immunity. Furthermore, the par-
ticipants we studied had nadir CD4 counts of .135 cells/mm3
(median 289 cells/mm3), and we did not have access to partic-
ipants commencing treatment at lower CD4 counts (e.g.,
,50 cells/mm3). These highly immunocompromised patients would
be the most relevant group to study with respect to susceptibility to
CMV disease. In this context, although CMV-specific cells replen-
ished more poorly than M. tuberculosis–specific cells after ART,
they were present at a high frequency prior to ART initiation, which
may well have been sufficient to provide protective immunity to
CMV. Moreover, the extent of CD4 depletion at the time of ART
initiation could impact the degree and dynamics of Ag-specific
CD4+ T cell recovery. Lastly, we delineated memory subsets
based on two markers, CD27 and CD45RO. These markers cannot
differentiate between central memory and transitional memory cells
within the CD27+CD45RO+ ED subset, and inclusion of a marker
such as CCR7 would afford an additional degree of distinction that
may reveal further differences in the ability of these memory subsets
to expand after ART and should be included in future studies of
reconstitution of pathogen-specific immunity. Further research ad-
dressing these important limitations is needed to confirm and extend
our findings.
Understanding the host and cellular factors that contribute to
successful immune restoration on effective antiretroviral treatment
for HIV, including both the overall CD4+ T cell compartment and
copathogen-specific CD4 immunity, is of crucial importance, as
only partial recovery of these cells could result in a persistently
heightened risk of particular opportunistic infections. In this re-
port, we showed that the renewal potential of pre-existing pathogen-
specific CD4+ T cells was related to their memory differentiation
profile. It will be important to determine whether this principle
holds true in a wider context for other copathogens. Incomplete
restoration of functional immunity and the persistence of elevated
susceptibility to particular coinfections have implications for tar-
geted interventions in the treated HIV-infected population. Over-
all, our findings underscore the complexity of immune reconstitution
on ART and the importance of preserving functional immunity
with early ART (66).
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